Hepatitis B virus screening before adjuvant chemotherapy in patients with early-stage breast cancer: a cost-effectiveness analysis

Breast Cancer Research and Treatment

Volumn 151, Issue 3, 2015, Pages 639-652

  Wong, William W L ^a,b   Hicks, Lisa K ^c   Tu, Hong Anh ^d   Pritchard, Kathleen I ^e   Krahn, Murray D ^a,b,d   Feld, Jordan J ^f   Chan, Kelvin K ^e  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^f UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Adjuvant chemotherapy; Cost effectiveness; Early stage breast cancer; Hepatitis B reactivation

Indexed keywords

ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; TENOFOVIR; ANTIVIRUS AGENT; BIOLOGICAL MARKER;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER STAGING; CHRONIC HEPATITIS B; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG COST; HEPATITIS B VIRUS; HUMAN; INFECTION PREVENTION; LIFE EXPECTANCY; PRIORITY JOURNAL; PROCESS MODEL; QUALITY ADJUSTED LIFE YEAR; SCREENING TEST; VIRUS DIAGNOSIS; VIRUS LOAD; VIRUS REACTIVATION; AGED; BREAST NEOPLASMS; CANADA; COMPLICATION; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; HEALTH CARE COST; HEPATITIS B; LIVER CIRRHOSIS; LIVER NEOPLASMS; MASS SCREENING; MIDDLE AGED; PATHOLOGY; PREVALENCE; REPRODUCIBILITY; STATISTICAL MODEL;

AGED; ANTIVIRAL AGENTS; BIOMARKERS; BREAST NEOPLASMS; CANADA; COST-BENEFIT ANALYSIS; FEMALE; HEALTH CARE COSTS; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MASS SCREENING; MIDDLE AGED; MODELS, STATISTICAL; NEOPLASM STAGING; PREVALENCE; REPRODUCIBILITY OF RESULTS;

EID: 84930276846     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-015-3382-7     Document Type: Article

References (86)

1. Bray F, Jemal A, Grey N, Ferlay J, Forman D (2012) Global cancer transitions according to the human development index (2008–2030): a population-based study. Lancet Oncol 13:790–801
2. Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M et al (2005) Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 353:1784–1792
3. Bonneterre J, Roche H, Kerbrat P, Bremond A, Fumoleau P, Namer M et al (2005) Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial. J Clin Oncol 23:2686–2693
4. G. Early Breast Cancer Trialists’ Collaborative, Peto R, Davies C, Godwin J, Gray R, Pan HC et al (2012) Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 379:432–444
5. Wong WW, Woo G, Heathcote EJ, Krahn M (2013) Disease burden of chronic hepatitis B among immigrants in Canada. Can J Gastroenterol 27:137–147
6. Lubel JS, Testro AG, Angus PW (2007) Hepatitis B virus reactivation following immunosuppressive therapy: guidelines for prevention and management. Intern Med J 37:705–712
7. Hoofnagle JH, Dusheiko GM, Schafer DF, Jones EA, Micetich KC, Young RC et al (1982) Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann Intern Med 96:447–449
8. Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D (1991) Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 100:182–188
9. Kwak LW, Halpern J, Olshen RA, Horning SJ (1990) Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. J Clin Oncol 8:963–977
10. Lau GK, Yiu HH, Fong DY, Cheng HC, Au WY, Lai LS et al (2003) Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 125:1742–1749
11. Loomba R, Rowley A, Wesley R, Liang TJ, Hoofnagle JH, Pucino F et al (2008) Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 148:519–528
12. Rotermann M, Langlois K, Andonov A, Trubnikov M (2013) Seroprevalence of hepatitis B and C virus infections: results from the 2007 to 2009 and 2009 to 2011 Canadian Health Measures Survey. Health Rep 24(11):3–13
13. “TreeAge (2013) Professional” Williamstown, MA: TreeAge Software, 2013
14. Benvegnu L, Gios M, Boccato S, Alberti A (2004) Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut 53:744–749
15. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN et al (2006) Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295:65–73
16. Chu CM, Liaw YF (2007) Chronic hepatitis B virus infection acquired in childhood: special emphasis on prognostic and therapeutic implication of delayed HBeAg seroconversion. J Viral Hepat 14:147–152
17. Craxi A, Colombo P, D’Amico G, Di Blasi F, Di Marco V, Magrin S et al (1987) Hepatitis B infection and liver cirrhosis: a reappraisal from the Mediterranean area. Ann Ist Super Sanita 24:257–265
18. D’Amico G, Morabito A, Pagliaro L, Marubini E (1986) Survival and prognostic indicators in compensated and decompensated cirrhosis. Dig Dis Sci 31:468–475
19. Fattovich G, Giustina G, Schalm SW, Hadziyannis S, Sanchez-Tapias J, Almasio P et al (1995) Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP study group on hepatitis B virus and cirrhosis. Hepatology 21:77–82
20. Fattovich G, Pantalena M, Zagni I, Realdi G, Schalm SW, Christensen E (2002) Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. Am J Gastroenterol 97:2886–2895
21. Hutton DW, Tan D, So SK, Brandeau ML (2007) Cost-effectiveness of screening and vaccinating Asian and Pacific Islander adults for hepatitis B. Ann Intern Med 147:460–469
22. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ (2006) Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 130:678–686
23. Jacobs RJ, Saab S, Meyerhoff AS (2003) The cost effectiveness of hepatitis immunization for US college students. J Am Coll Health 51:227–236
24. Kanwal F, Farid M, Martin P, Chen G, Gralnek IM, Dulai GS et al (2006) Treatment alternatives for hepatitis B cirrhosis: a cost-effectiveness analysis. Am J Gastroenterol 101:2076–2089
25. Kanwal F, Gralnek IM, Martin P, Dulai GS, Farid M, Spiegel BM (2005) Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis. Ann Intern Med 142:821–831
26. Liaw YF, Tai DI, Chu CM, Chen TJ (1988) The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology 8:493–496
27. Liaw YF, Tai DI, Chu CM, Lin DY, Sheen IS, Chen TJ et al (1986) Early detection of hepatocellular carcinoma in patients with chronic type B hepatitis. A prospective study. Gastroenterology 90:263–267
28. Lin SM, Sheen IS, Chien RN, Chu CM, Liaw YF (1999) Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 29:971–975
29. Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML et al (2003) Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 348:808–816
30. Margolis HS, Coleman PJ, Brown RE, Mast EE, Sheingold SH, Arevalo JA (1995) Prevention of hepatitis B virus transmission by immunization. An economic analysis of current recommendations. JAMA 274:1201–1208
31. McMahon BJ, Holck P, Bulkow L, Snowball M (2001) Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus. Ann Intern Med 135:759–768
32. Papatheodoridis GV, Manolakopoulos S, Touloumi G, Vourli G, Raptopoulou-Gigi M, Vafiadis-Zoumbouli I et al (2011) Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study. Gut 60:1109–1116
33. Notifiable diseases on-line (Online) Public Health Agency of Canada, Ottawa. http://dsol-smed.phac-aspc.gc.ca/dsol-smed/ndis/c_time-eng.php
34. Pisu M, Meltzer MI, Lyerla R (2002) Cost-effectiveness of hepatitis B vaccination of prison inmates. Vaccine 21:312–321
35. Veenstra DL, Spackman DE, Di Bisceglie A, Kowdley KV, Gish RG (2008) Evaluating anti-viral drug selection and treatment duration in HBeAg-negative chronic hepatitis B: a cost-effectiveness analysis. Aliment Pharmacol Ther 27:1240–1252
36. Veenstra DL, Sullivan SD, Clarke L, Iloeje UH, Tafesse E, Di Bisceglie A et al (2007) Cost effectiveness of entecavir versus lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis B. Pharmacoeconomics 25:963–977
37. Wen WH, Chang MH, Hsu HY, Ni YH, Chen HL (2004) The development of hepatocellular carcinoma among prospectively followed children with chronic hepatitis B virus infection. J Pediatr 144:397–399
38. Yuen MF, Yuan HJ, Hui CK, Wong DK, Wong WM, Chan AO et al (2003) A large population study of spontaneous HBeAg seroconversion and acute exacerbation of chronic hepatitis B infection: implications for antiviral therapy. Gut 52:416–419
39. Younis T, Rayson D, Sellon M, Skedgel C (2008) Adjuvant chemotherapy for breast cancer: a cost-utility analysis of FEC-D vs. FEC 100. Breast Cancer Res Treat 111:261–267
40. Early Breast Cancer Trialists’ Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717
41. Roche H, Fumoleau P, Spielmann M, Canon JL, Delozier T, Serin D et al (2006) Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 trial. J Clin Oncol 24:5664–5671
42. Gigi E, Lalla T, Orphanou E, Sinakos E, Vrettou E, Raptopoulou-Gigi M (2007) Long term follow-up of a large cohort of inactive HBsAg (+)/HBeAg (−)/anti-HBe (+) carriers in Greece. J Gastrointest Liver Dis 16:19–22
43. Hsu YS, Chien RN, Yeh CT, Sheen IS, Chiou HY, Chu CM et al (2002) Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 35:1522–1527
44. Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC et al (2006) A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 354:1001–1010
45. Chang TT, Lai CL, Kew Yoon S, Lee SS, Coelho HS, Carrilho FJ (2010) Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 51:422–430
46. Ren FY, Piao DM, Piao XX (2007) A one-year trial of entecavir treatment in patients with HBeAg-positive chronic hepatitis B. World J Gastroenterol 13:4264–4267
47. Woo G, Tomlinson G, Nishikawa Y, Kowgier M, Sherman M, Wong DKH et al (2010) Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses. Gastroenterology 139:1218–1229
48. Chang TT, Liaw YF, Wu SS, Schiff E, Han KH, Lai CL et al (2010) Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 52:886–893
49. Hosaka T, Suzuki F, Kobayashi M, Seko Y, Kawamura Y, Sezaki H et al (2013) Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology 58:98–107
50. Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z et al (2006) Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 354:1011–1020
51. Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z et al (2008) Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 359:2442–2455
52. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H et al (2004) Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351:1521–1531
53. Zurawska U, Hicks LK, Woo G, Bell CM, Krahn M, Chan KK et al (2012) Hepatitis B virus screening before chemotherapy for lymphoma: a cost-effectiveness analysis. J Clin Oncol 30:3167–3173
54. Zeuzem S, Buti M, Ferenci P, Sperl J, Horsmans Y, Cianciara J et al (2006) Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 44:97–103
55. Chu CM, Liaw YF (2006) Hepatitis B virus-related cirrhosis: natural history and treatment. Semin Liver Dis 26:142–152
56. Fattovich G (2003) Natural history of hepatitis B. J Hepatol 39(Suppl 1):S50–S58
57. Fattovich G, Brollo L, Giustina G, Noventa F, Pontisso P, Alberti A et al (1991) Natural history and prognostic factors for chronic hepatitis type B. Gut 32:294–298
58. Villeneuve JP (2005) The natural history of chronic hepatitis B virus infection. J Clin Virol 34(Suppl 1):S139–S142
59. Liaw YF (2009) Natural history of chronic hepatitis B virus infection and long-term outcome under treatment. Liver Int 29(Suppl 1):100–107
60. Fattovich G, Bortolotti F, Donato F (2008) Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 48:335–352
61. Grieco EM, Acosta YD, Cruz GP, Gambino C, Gryn T, Larsen LJ et al (2012) The foreign-born population in the United States: 2010. U.S. Department of Commerce, Economics and Statistics Administration, U.S. CENSUS BUREAU, Washington, DC
62. Wasley A, Kruszon-Moran D, Kuhnert W, Simard EP, Finelli L, McQuillan G et al (2010) The prevalence of hepatitis B virus infection in the United States in the era of vaccination. J Infect Dis 202:192–201
63. Laupacis A, Feeny D, Detsky AS, Tugwell PX (1992) How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 146:473–481
64. McCabe C, Claxton K, Culyer AJ (2008) The NICE cost-effectiveness threshold: what it is and what that means. Pharmacoeconomics 26:733–744
65. (2005) Choosing interventions that are cost effective (WHO-CHOICE). World Health Organization, Geneva
66. Day FL, Karnon J, Rischin D (2011) Cost-effectiveness of universal hepatitis B virus screening in patients beginning chemotherapy for solid tumors. J Clin Oncol 29:3270–3277
67. Lok AS, McMahon BJ (2007) Chronic hepatitis B. Hepatology 45:507–539
68. Artz AS, Somerfield MR, Feld JJ, Giusti AF, Kramer BS, Sabichi AL et al (2010) American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases. J Clin Oncol 28:3199–3202
69. Hicks LK et al (2015) Estimating the risk of HBV reactivation in patients receiving chemotherapy for solid tumors: a metaanalysis, to be submitted
70. Gagnon YM, Levy AR, Iloeje UH, Briggs AH (2004) Treatment costs in Canada of health conditions resulting from chronic hepatitis B infection. J Clin Gastroenterol 38:S179–S186
71. Common Drug Review Drug Database (Online) Canadian Agency for Drugs and Technologies in Health, Ottawa. https://www.cadth.ca/cdr/reports
72. Buti M, Brosa M, Casado MA, Rueda M, Esteban R (2009) Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B. J Hepatol 51:640–646
73. Schedule of Laboratory Fees (Online). Government of Ontario, Toronto. http://www.health.gov.on.ca/english/providers/program/ohip/sob/lab/labfimmu.html
74. Wong WW, Woo G, Heathcote EJ, Krahn M (2011) Cost effectiveness of screening immigrants for hepatitis B. Liver Int 31:1179–1190
75. (2004) In: Healthcare in Canada, Canadian Institute for Health Information, Ottawa
76. Cancer Care Ontario (2014) Drug formulary. https://www.cancercare.on.ca/toolbox/drugformulary/. Accessed 04 Feb 2014
77. Cocquyt V, Moeremans K, Annemans L, Clarys P, Van Belle S (2003) Long-term medical costs of postmenopausal breast cancer therapy. Ann Oncol 14:1057–1063
78. Will BP, Berthelot JM, Le Petit C, Tomiak EM, Verma S, Evans WK (2000) Estimates of the lifetime costs of breast cancer treatment in Canada. Eur J Cancer 36:724–735
79. Woo G, Tomlinson G, Yim C, Lilly L, Therapondos G, Wong DKH et al (2012) Health state utilities and quality of life in patients with hepatitis B. Can J Gastroenterol 26:445–451
80. Hillner BE, Smith TJ, Desch CE (1992) Efficacy and cost-effectiveness of autologous bone marrow transplantation in metastatic breast cancer. Estimates using decision analysis while awaiting clinical trial results. JAMA 267:2055–2061
81. Hind D, Ward S, De Nigris E, Simpson E, Carroll C, Wyld L (2007) Hormonal therapies for early breast cancer: systematic review and economic evaluation. Health Technol Assess 11:iii–iv, ix–xi, 1–134
82. Tengs TO, Wallace A (2000) One thousand health-related quality-of-life estimates. Med Care 38:583–637
83. Sorensen SV, Brown R, Benedict A, Flood E, Revicki D (2004) Patient-rated utilities in postmenopausal early breast cancer (EBC): a cross-country comparison. Value Health 7:641–642
84. Hillner BE, Smith TJ (1991) Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. A decision-analysis model. N Engl J Med 324:160–168
85. Lidgren M, Wilking N, Jonsson B, Rehnberg C (2007) Health related quality of life in different states of breast cancer. Qual Life Res 16:1073–1081
86. Burstrom K, Johannesson M, Diderichsen F (2006) A comparison of individual and social time trade-off values for health states in the general population. Health Policy 76:359–370